Resistance mechanisms and epidemiology of multiresistant pathogens in europe and efficacy of tigecycline in observational studies

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL.2, 2013, Pages

  Heizmann, Wolfgang R ^a   Dupont, Hervé ^b   Montravers, Philippe ^c   Guirao, Xavier ^d,e   Eckmann, Christian ^f   Bassetti, Matteo ^g   SánchezGarcía, Miguel ^h   Capparella, Maria Rita ⁱ   Simoneau, Damien ⁱ   Bodmann, Klaus Friedrich ^j  

^a Center for Microbiology and Infectious Diseases   (Germany)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^f Klinikum Peine   (Germany)

^g SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ PFIZER INC   (United States)

^j Werner Forssmann Hospital   (Germany)

more..

Author keywords

Broad spectrum antibacterial therapy; Complicated intra abdominal infections; Complicated skin and soft tissue infections; Non interventional studies; Polymicrobial infections

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TIGECYCLINE;

ABDOMINAL INFECTION; ARTICLE; COMBINATION CHEMOTHERAPY; COMPLICATED INTRA ABDOMINAL INFECTION; COMPLICATED SKIN AND SOFT TISSUE INFECTION; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; EUROPE; HUMAN; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS;

BROAD-SPECTRUM ANTIBACTERIAL THERAPY; COMPLICATED INTRA-ABDOMINAL INFECTIONS; COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS; NON-INTERVENTIONAL STUDIES; POLYMICROBIAL INFECTIONS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 84879359533     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt144     Document Type: Article

References (89)

1. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
2. Vonberg RP, Wolter A, Chaberny IF, et al. Epidemiology of multidrug- resistant gram-negative bacteria: data from an university hospital over a 36-month period. Int J Hyg Environ Health 2008; 211: 251-7.
3. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
4. Jevons PM. "Celbenin"-resistant staphylococci. Br Med J 1961; 1: 124-5.
5. Couto I,Wu SW, Tomasz A, et al. Development of methicillin resistance in clinical isolates of Staphylococcus sciuri by transcriptional activation of the mecA homologue native to the species. J Bacteriol 2003; 185: 645-53.
6. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57: 7-13.
7. Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15: pii-19688.
8. Armand-Lefevre L, Buke C, Ruppe E, et al. Secular trends and dynamics of hospital associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2010; 16: 1435-41.
9. Wilson J, Elgohari S, Livermore DM, et al. Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin Microbiol Infect 2011; 17: 451-8.
10. Freixas N, Sopena N, Limon E, et al. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) in acute care hospitals. Results of the VINCat Program (2008-2010). Enferm Infecc Microbiol Clin 2012; 30 Suppl 3: 39-42.
11. Mattner F, Bange FC, Meyer E, et al. Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology. Dtsch Arztebl Int 2012; 109: 39-45.
12. Moellering RC Jr. MRSA: the first half century. J Antimicrob Chemother 2012; 67: 4-11.
13. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii-19044.
14. Diestra K, Miro E, Marti C, et al. Multiclonal epidemic of Klebsiella pneumoniae isolates producing DHA-1 in a Spanish hospital. Clin Microbiol Infect 2011; 17: 1032-6.
15. Mata C, Miro E, Toleman M, et al. Association of blaDHA-1 and qnrB genes carried by broad-host-range plasmids among isolates of Enterobacteriaceae at a Spanish hospital. Clin Microbiol Infect 2011; 17: 1514-7.
16. Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009). Int J Antimicrob Agents 2012; 39: 115-23.
17. Meyer E, Schwab F, Schroeren-Boersch B, et al. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 2010; 14: R113.
18. Angel DM, Ramon HJ, Martinez-Martinez L, et al. [Extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin 2009; 27: 503-10.
19. Webster DP, Young BC, Morton R, et al. Impact of a clonal outbreak of extended-spectrum b-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother 2011; 66: 2126-35.
20. Skov R, Hansen DS. [Still increasing incidence of MRSA and ESBL-producing Enterobacteriaceae in society and in hospital-associated cases]. Ugeskr Laeger 2011; 173: 2869-72.
21. van der Bij AK, Peirano G, Goessens WH, et al. Clinical and molecular characteristics of extended-spectrum-b-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam area, Netherlands. Antimicrob Agents Chemother 2011; 55: 3576-8.
22. Archibald L, Phillips L, MonnetDet al. Antimicrobial resistance in isolates frominpatientsandoutpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-5.
23. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing b-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61.
24. Cuzon G, Naas T, Truong H, et al. Worldwide diversity of Klebsiella pneumoniae that produce b-lactamase blaKPC-2 gene. Emerg Infect Dis 2010; 16: 1349-56.
25. Naas T, Cattoen C, Bernusset S, et al. First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France. Antimicrob Agents Chemother 2012; 56: 1664-5.
26. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D b-lactamases. Antimicrob Agents Chemother 2010; 54: 24-38.
27. Poirel L, Heritier C, Tolun V, et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
28. Carrer A, Poirel L, Yilmaz M, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 2010; 54: 1369-73.
29. Pfeifer Y, Schlatterer K, Engelmann E, et al. Emergence of OXA-48-type carbapenemase-producing Enterobacteriaceae in German hospitals. Antimicrob Agents Chemother 2012; 56: 2125-8.
30. Cuzon G, Ouanich J, Gondret R, et al. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 2011; 55: 2420-3.
31. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-b-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-54.
32. Hammami S, Boutiba-Ben BI, Ghozzi R, et al. Nosocomial outbreak of imipenem-resistant Pseudomonas aeruginosa producing VIM-2 metallob- lactamase in a kidney transplantation unit. Diagn Pathol 2011; 6: 106.
33. Nordmann P, Boulanger AE, Poirel L. NDM-4 metallo-b-lactamase with increased carbapenemase activity from Escherichia coli. Antimicrob Agents Chemother 2012; 56: 2184-6.
34. Hornsey M, Phee L, Wareham DW. A novel variant, NDM-5, of the New Delhi metallo-b-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob Agents Chemother 2011; 55: 5952-4.
35. Pitart C, Sole M, Roca I, et al. First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 b-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 2011; 55: 4398-401.
36. Lee EH, Nicolas MH, Kitzis MD, et al. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother 1991; 35: 1093-8.
37. Yang FC, Yan JJ, Hung KH, et al. Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital. J Clin Microbiol 2012; 50: 223-6.
38. Cuzon G, Naas T, Bogaerts P, et al. Plasmid-encoded carbapenemhydrolyzing b-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother 2008; 52: 3463-4.
39. Livermore DM. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009; 64 Suppl 1: i29-36.
40. Pfeifer Y, WitteW, HolfelderMet al. NDM-1-producing Escherichia coli in Germany. Antimicrob Agents Chemother 2011; 55: 1318-9.
41. Poirel L, Schrenzel J, Cherkaoui A, et al. Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J Antimicrob Chemother 2011; 66: 1730-3.
42. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
43. Livermore DM, Walsh TR, Toleman M, et al. Balkan NDM-1: escape or transplant?. Lancet Infect Dis 2011; 11: 164.
44. Aslangul E, Baptista M, Fantin B, et al. Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997; 175: 598-605.
45. Chen YH, Lu PL, Huang CH, et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob Agents Chemother 2012; 56: 1452-7.
46. Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 2003; 52: 382-8.
47. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
48. Finks J, Wells E, Dyke TL, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis 2009; 15: 943-5.
49. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res 2011; 134: 704-8.
50. KatayamaY,Murakami-KurodaH, Cui Let al. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother 2009; 53: 3190-6.
51. Cui L,MurakamiH,Kuwahara-AraiKet al.Contribution ofathickenedcell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276-85.
52. Protonotariou E, Dimitroulia E, Pournaras S, et al. Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus faecium in Greece between 2002 and 2007. J Hosp Infect 2010; 75: 225-7.
53. Bourdon N, Fines-Guyon M, Thiolet JM, et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother 2011; 66: 713-21.
54. Kawecki D, Kwiatkowski A, Sawicka-Grzelak A, et al. Urinary tract infections in the early posttransplant period after kidney transplantation: etiologic agents and their susceptibility. Transplant Proc 2011; 43: 2991-3.
55. Lambiase A, Del PM, Piazza O, et al. Typing of vancomycin-resistant Enterococcus faecium strains in a cohort of patients in an Italian intensive care unit. Infection 2007; 35: 428-33.
56. Guimaraes B, Barreto A, Radhouani H, et al. Genetic detection of extended-spectrum b-lactamase-containing Escherichia coli isolates and vancomycin-resistant enterococci in fecal samples of healthy children. Microb Drug Resist 2009; 15: 211-6.
57. Goossens H, Jabes D, Rossi R, et al. European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J Antimicrob Chemother 2003; 51 Suppl 3: iii5-12.
58. Meyer E, Ziegler R, Mattner F, et al. Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycinresistant Enterococcus faecium or extended-spectrum b-lactamaseproducing Enterobacteriaceae. Infection 2011; 39: 501-6.
59. Gallon O, Lamy B, Laurent F, et al. Antimicrobial susceptibility profiles of Staphylococcus aureus isolated in 2007 from French patients with bloodstream infections: goodbye hVISA, welcome Geraldine?. J Antimicrob Chemother 2010; 65: 1297-9.
60. Lewis T, Chaudhry R, Nightingale P, et al. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. Int J Infect Dis 2011; 15: e131-5.
61. Hawser SP, Bouchillon SK, Hoban DJ, et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37: 219-24.
62. Campanile F, Borbone S, PerezMet al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents 2010; 36: 415-9.
63. Tygacil Summary of Product Characteristics. Sandwich, Kent, UK: Pfizer Ltd, 2012.
64. European Medicines Agency. Questions and Answers on the Review of Tygacil (Tigecycline): Outcome of a Renewal Procedure (17 February 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000644/WC500102228.pdf (22 March 2012, date last accessed).
65. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
66. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
67. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
68. Towfigh S, Pasternak J, Poirier A, et al. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010; 16: 1274-81.
69. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
70. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
71. Cai Y,Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-72.
72. US FDA. FDA Drug Safety Communication: Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections (1 September 2010). http://www.fda.gov/drugs/drugsafety/ucm224370.htm (26 September 2012 date last accessed).
73. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
74. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012; 54: 1672-4.
75. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
76. European Medicines Agency. EPAR Summary for the Public: Tygacil (last updated February 2012). http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/000644/WC500044509. pdf (6 November 2012, date last accessed).
77. Bassetti M, Nicolini L, Repetto E, et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10: 287.
78. Bodmann KF, Heizmann WR, von Eiff C, et al. Therapy of 1025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy 2012; 58: 282-94.
79. Eckmann C, Heizmann WR, Leitner E, et al. Prospective, noninterventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 2011; 57: 275-84.
80. Montravers P, Dupont H, Bedos JP, et al. Use of tigecycline in intensive care: a French prospective observational study. Clin Microbiol Infect 2012; 18: 767-8.
81. Sanchez Garcia M, on behalf of the Tigecycline in Critically Ill Patients Study Group. Observational study of the use of tigecycline (TGC) in critically ill patients (CIP). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract K-1412. American Society for Microbiology, Washington, DC, USA.
82. Bassetti M, Eckmann C, Bodmann KF, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii5-14.
83. Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii25-35.
84. Montravers P, Bassetti M, Dupont H, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii15-24.
85. Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrugresistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosaclinical isolates. Eur J Clin Microbiol Infect Dis 2012;31:695-701.
86. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-803.
87. Sanchez-Porto A,Casanova-RomanM,Casas-Ciria J, et al. Invitroactivity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis. Infez Med 2010; 18: 108-12.
88. EUCAST. Breakpoint Tables for Interpretations of MICs and Zone Diameters. http://www.eucast.org/clinical_breakpoints/(November 2012, date last accessed).
89. Perri MB, Hershberger E, Ionescu M, et al. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002; 42: 269-71.